A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies

作者：Bot Adrian^*; Ahn Mark; Bosch Marnix; Brockstedt Dirk; Butterfield Lisa H; Cornforth Andrew; Harrop Richard; Kast W Martin; Koya Richard; Marincola Francesco; Margolin Kim; McCoy Candice; Pawelec Graham; Rothman John; Ramirez Montagut Teresa; Schlom Jeffrey; Srivastava Pramod; Wallis Sarah; Walter Steffen; Wang Ena; Waslif John

来源：Journal of Translational Medicine, 2012, 10: 218.

DOI：10.1186/1479-5876-10-218

While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership from academia and industry, to identify, share and discuss most current priorities in research and translation of novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.

• 出版日期2012-11-5